Key result
Adding bisphosphonates to romosozumab is proposed to reduce adverse cardiovascular risks.
Osteoporosis and cardiovascular diseases are major public health issues. Bone and cardiovascular remodeling share multiple biological markers and pathways. Medical intervention, such as using romosozumab, an antisclerostin antibody, improves the clinical outcome of osteoporosis. However, blocking sclerostin leads to Wnt (wingless/integrated) activation and participation in the cardiovascular remodeling process, which could potentially lead to adverse events. Based on the opposing roles of bisphosphonates and the Wnt pathway on endothelial dysfunction, lipid accumulation and calcification of the vessel walls, the combination of romosozumab and bisphosphonates could be a new therapeutic approach to reducing the risks of adverse cardiovascular events in romosozumab receivers. Visual Overview- An online visual overview is available for this article.
No takes yet. Share an insight, caveat, or question.
Asadipooya et al. (2019) conducted a review in Osteoporosis and cardiovascular diseases. Combination of romosozumab and bisphosphonates was evaluated. The combination of romosozumab and bisphosphonates is proposed as a potential therapeutic approach to reduce the risks of adverse cardiovascular events in patients receiving romosozumab.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: